Lenvatinib 4mg capsules | Lenvatinib | Millionpharma

1
Lenvatinib 4mg capsules Lenvatinib
Millionpharma
2
DESCRIPTION

• Lenvatinib 4mg is a multi-kinase inhibitor and
  antineoplastic agents. It is a type of targeted
  treatment which target the specific cancer cells
  and hence reduces side effects caused by affected
  cells.Lenvatinib 4mg inhibits the protein which
  promotes cell division by preventing the cancer
  cell development.

3
(No Transcript)
4
PRESCRIBED FOR

• In adult, Lenvatinib 4mg tablet  is indicated for
  the treatment of metastatic, progressive,
  radioactive Differentiated Thyroid
  cancer.Lenvatinib 4mg in combination with
  everolimus is indicated in patients for the
  treatment of advance Renal Cell Carcinoma
  following treatment before anti-angiogenic
  therapy.

5

• Lenvatinib 4mg is also indicated for the first
  line treatment in patients suffering with
  unresectable hepatocellular carcinoma.

6
(No Transcript)
7
MECHANISM OF ACTION

• Lenvatinib is a tyrosine kinase inhibitor which
  has shown mainly anti-angiogenic properties, and
  direct prevention of malignant developed was also
  observed inside the models. Lenvatinib which
  selectively prevents the kinase functions of
  vascular endothelial growth factor receptors
  1(FLT1), 2 (KDR), 3 (FLT4).

8

• Although not been studied directly with
  Lenvatinib, the mechanism of action (MOA) for
  High blood pressure is hypothesizing to be
  resolve by the prevention of VEGFR2 in vascular
  endothelial cells. Same as the, the action for
  proteinuria is hypothesizing to be interfere with
  down regulation of VEGFR1 and VEGFR2 in the cell
  of bowmans capsules of the glomerulus.

9
(No Transcript)
10
PROPERTIES

• Ingredients  Lenvatinib 
• Strength  4mg 
• Package  Pack of 20 Capsules.

11
ADD ME

• Absorption Time to high plasma concentration is
  1-4 hours post dose. Effect with food is low to
  the extent Lenvatinib 4mg of absorption.
• Distributionbounding of Human plasma proteins
  is 98 to 99.

12
ADD ME

• MetabolismLenvatinib 4mg is primarily
  metabolized in CYP3A. Lenvatinib 4mg metabolic
  pathway is identified as enzymatic and
  non-enzymatic processes.
• Elimination eliminated via 64 feces and 25
  urine.

13
DOSAGE MANAGEMENT

• The usual dose of Lenvatinib for the adult
  patients is 24mg and administer has two 10mg
  capsules and one 4mg capsule given orally, once
  daily taken with or without food.The Lenvatinib
  tablet should continue until disease progression
  or until unacceptable toxicity occurs.

14
(No Transcript)
15

• Take Lenvatinib tablet at the same time.Patients
  with severe renal or hepatic impairment the dose
  is 14mg administer once daily orally.
• OVERDOSE Lenvatinib is not expected to be
  dialyzable because of maximum plasma protein
  binding and if the dose getting of Lenvatinib
  4mg orally then causes death due to multiorgan
  dysfunction occurred in the patients.

16
PRECAUTIONS

• Blood pressure may increase while treatment
  with Lenvatinib 4mg tablet. Your doctor will
  preferably check your blood pressure during your
  treatment.
• Inform the doctor if you are allergic
  to Lenvatinib 4mg, any other regimens, or any of
  the ingredients in Lenvatinib 4mg capsules.
• Other prescription and nonprescription
  medications, vitamins, nutritional supplements,
  and herbal products you are taking or plan to
  take. Your doctor may to change the doses of your
  drugs or guide carefully for adverse reaction.

17

• Inform doctor if you have or had seizures,
  hypertension, a stroke, a heart attack, ,
  especially those due to blood clots, a fistula, a
  tear in the wall of your GIT, QT interval
  prolongation (an irregular heart rhythm that can
  lead to fainting, loss of consciousness,
  seizures, or sudden death), low levels of Ca, K
  or Mg in your blood, bleeding problems, or
  cardiac, renal, or hepatic disease..

18

• Take into the knowledge that Lenvatinib 4mg may
  reduce the fertility in men and women. It not
  means that you or your partner cannot become
  pregnant. Inform doctor before if you are
  pregnant or plan to become pregnant. After
  becoming pregnant, you should use birth control
  while treatment with Lenvatinib 4mg and for at
  least 2 weeks after your treatment, become
  pregnant during Lenvatinib therapy, call your
  doctor immediately. Lenvatinib 4mg may harm the
  fetus.

19
(No Transcript)
20

• Inform the doctor if you are breastfeeding or
  plan to breastfeed. Avoid breastfeed
  during Lenvatinib 4mg treatment

21
SIDE EFFECTS

• Common side effectsTirednessPeeling of skin on
  palms and sole of the feetConstipationLoss of
  appetiteWeight lossJoint and muscle
  painInsomnia.

22
Serious side effects

• Shortness of breathChest painPain in arm,
  back, neck or jawSeizures Black, tarry or
  bloody stoolsHeavy menstrual bleedingCoughing
  up bloodYellowing of the skin or eyes.

23

• PREGNANCY
• When administrated to pregnant, Lenvatinib
  4mg drugs can cause harm to the fetal. There are
  no available human data related to drug
  associated risk. Advice pregnant women specific
  risk to fetus.

24

• LACTATION
• Excretion in human milk is unknown. Its not
  known that drug is present in human milk Because
  of the serious side effects in infants from the
  drug, Advice to avoid breast feeding during
  treatment with Lenvatinib 4mg.

25

• STORAGE
• Store at 25CKeep out of the children hands
  Discard the after-expiry date Dispense the drug
  only in original container

26
CONTACT US

• EMAIL millionhealthpharmaceuticals_at_gmail.
  com
• PHONE NO 91-9940472902 
• WEBSITE https//millionpharma.com/lenvatinib-4mg.
  php

27
(No Transcript)